Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N
Free University Hospital, Netherlands Cancer Institute, Amsterdam.
J Clin Oncol. 1996 Mar;14(3):814-20. doi: 10.1200/JCO.1996.14.3.814.
Thymomas are rare neoplasms of the mediastinum. The role of chemotherapy in advanced thymomas is not fully established.
In the European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Cooperative Group, 16 patients with recurrent or metastatic malignant thymoma were entered over 6 years onto a study of combination chemotherapy that consisted of cisplatin 60 mg/m2 on day 1 and etoposide 120 mg/m2 on days 1, 2, and 3, every 3 weeks.
A median of six courses per patient was administered. Main side effects of treatment were leukopenia, nausea and vomiting, and alopecia. Five complete responses and four partial responses were obtained, with a median response duration of 3.4 years. The median progression-free survival and survival times were 2.2 years and 4.3 years, respectively, with a median follow-up duration of 7 years.
The combination of cisplatin and etoposide is highly effective and well tolerated in advanced thymoma. The investigation of this combination in a neoadjuvant setting in unresectable invasive thymoma is warranted.
胸腺瘤是纵隔的罕见肿瘤。化疗在晚期胸腺瘤中的作用尚未完全确立。
在欧洲癌症研究与治疗组织（EORTC）肺癌协作组中，16例复发性或转移性恶性胸腺瘤患者在6年期间进入一项联合化疗研究，该化疗方案为第1天给予顺铂60mg/m²，第1、2、3天给予依托泊苷120mg/m²，每3周重复一次。
每位患者中位接受六个疗程的治疗。治疗的主要副作用为白细胞减少、恶心呕吐和脱发。获得了5例完全缓解和4例部分缓解，中位缓解持续时间为3.4年。中位无进展生存期和总生存期分别为2.2年和4.3年，中位随访时间为7年。
顺铂和依托泊苷联合方案在晚期胸腺瘤中疗效显著且耐受性良好。在不可切除的侵袭性胸腺瘤新辅助治疗中对该联合方案进行研究是有必要的。
